Commercial/Healthcare Exchange PA Criteria

Effective: March 2008

Prior Authorization: Amrix & Fexmid

Products Affected: Amrix (cyclobenzaprine) extended-release oral capsules, cyclobenzaprine extended-release oral capsule, Fexmid (cyclobenzaprine) oral tablets, cyclobenzaprine 7.5mg oral tablet

Medication Description: Cyclobenzaprine is a central nervous system (CNS) muscle relaxant intended for short-term use in the treatment of pain, tenderness and limitation of motion caused by muscle spasms.

Covered Uses: Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Exclusion Criteria:

1. Use for periods longer than two or three weeks
2. Treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.
3. Hypersensitivity to cyclobenzaprine
4. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation
5. Use during the acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure
6. Hyperthyroidism

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions: Amrix: 18 years of age and older, Fexmid: 15 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 1 month

Other Criteria:

1. Patient has had a trial and failure of, contraindication, or intolerance to, immediate release cyclobenzaprine 5mg OR 10mg tablets; **AND**
2. Patient has had a trial and failure of, contraindication, or intolerance to at least TWO other muscle relaxants (e.g., baclofen 10mg, 20mg tablets, carisoprodol 350mg tablets, methocarbamol 500mg,750mg tablets, diazepam 2mg, 5mg, 10mg tablets).

References:

1. Amrix® extended release capsules [package insert]. Vandalia, OH: Cephalon, Inc.
2. Facts and Comparisons online

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	3/2008
2	Annual Review	Moved to new template CCI Revision Record: 9/08, 11/16	All	2/3/2020
3	Update	Added cyclobenzaprine 7.5mg oral tablet and cyclobenzaprine extended-release oral capsule to products affected Updated Other Criteria section from Patient has a documented adequate trial of, or has shown an intolerance to, and at least TWO other muscle relaxants (tizanidine, baclofen, orphenadrine, carisoprodol, methocarbamol, chlorzoxazone, diazepam, or metaxalone) **to** Patient has a documented adequate trial of, or has shown an intolerance to, and at least TWO other muscle relaxants (e.g. baclofen 10mg, 20mg tablet, carisoprodol 350mg tablet, methocarbamol 500mg, 750mg tablets, or diazepam 2mg, 5mg, 10mg tablets).	Products Affected Other Criteria	10/1/2020